NS-398: Cyclooxygenase-2 Independent Inhibition of Leukocyte Priming for Lipid Body Formation and Enhanced Leukotriene Generation
Overview
Authors
Affiliations
Because the induction of new lipid body formation in leukocytes correlates with and likely contributes to their enhanced 'primed' prostaglandin and leukotriene formation, we evaluated two selective cyclooxygenase (COX)-2 inhibitors. Three types of stimuli, cis -unsaturated fatty acids, platelet activating factor and protein kinase C activators, stimulate lipid body formation. NS-398 (0.1-10 microM), but not another COX-2 inhibitor, SC58125 (0.1- 10 microM), blocked leukocyte lipid body formation elicited by all three types of stimuli and also blocked priming for enhanced LTB(4) production and PGE(2) production. The effect of NS-398 on lipid body formation was independent of its inhibitory effects on COX-2 since arachidonate-induced lipid body formation in COX-2-deficient mouse leukocytes was also inhibited by NS-398. By means of its ability to inhibit leukocyte lipid body formation, NS-398 may exert actions independent of its COX-2 inhibition and more broadly contribute to the suppression of formation of COX-1 and lipoxygenase-derived eicosanoids.
Microglia-Derived Adiposomes are Potential Targets for the Treatment of Ischemic Stroke.
Lin C, Liao L, Yang T, Chang Y, Tung C, Hsu S Cell Mol Neurobiol. 2019; 39(5):591-604.
PMID: 30852719 PMC: 11462839. DOI: 10.1007/s10571-019-00665-9.
de Almeida P, Toledo D, Rodrigues G, DAvila H Front Microbiol. 2018; 9:499.
PMID: 29616011 PMC: 5869919. DOI: 10.3389/fmicb.2018.00499.
LEUKOCYTE LIPID BODIES - STRUCTURE AND FUNCTION AS "EICOSASOMES".
Weller P Trans Am Clin Climatol Assoc. 2017; 127:328-340.
PMID: 28066068 PMC: 5216467.
Heller S, Cable C, Penrose H, Makboul R, Biswas D, Cabe M Am J Physiol Gastrointest Liver Physiol. 2016; 310(10):G844-54.
PMID: 26968210 PMC: 4895869. DOI: 10.1152/ajpgi.00407.2015.
Urrutia R, Kalinec F Hear Res. 2015; 330(Pt A):26-38.
PMID: 25987503 PMC: 5391798. DOI: 10.1016/j.heares.2015.04.015.